Pharmacology Studies

Rigorous Pharmacology for Decision-Ready Preclinical Data

From target engagement profiling to full PK/PD characterisation, our pharmacology services generate the quantitative evidence your regulatory package demands.

Request a study design
Scientist analysing pharmacology dose-response data in a preclinical laboratory

A Full-Spectrum Pharmacology Package

Each service can be delivered as a standalone study or integrated into a comprehensive IND-enabling package.

Target Engagement & Binding

Receptor occupancy, binding kinetics and functional target engagement assays across in vitro and ex vivo systems. Selectivity profiling against related family members.

Request protocol →

Dose-Response Characterisation

EC50/IC50 determination, Hill slope analysis and full dose-response profiling in relevant pharmacological models. Therapeutic window definition with supporting PK data.

Request protocol →

PK/PD Modelling

Integrated pharmacokinetic/pharmacodynamic modelling linking plasma and tissue concentrations to efficacy and safety biomarkers. Non-compartmental and compartmental analyses.

Request protocol →

Safety Pharmacology

Core battery studies (CNS, cardiovascular, respiratory) aligned with ICH S7A and S7B guidelines. hERG channel assays, in vivo haemodynamic monitoring and respiratory function.

Request protocol →

Drug Combination Studies

Synergy and antagonism assessment using Chou-Talalay and Bliss independence models. Combination index calculations with full statistical reporting for mechanistic interpretation.

Request protocol →

Bioanalytical Support

LC-MS/MS quantification of small molecules and biologics in plasma, tissue and CSF. Method development and validation to GLP standards with full chain-of-custody documentation.

Request protocol →

Therapeutic Focus Areas

Deep disease-area knowledge informs every aspect of study design — from model choice to the pharmacological read-outs that matter most to regulators and partners.

Oncology

Antitumour pharmacology for small molecules, biologics and cell therapies. Exposure-efficacy relationships, resistance mechanism profiling and combination regimen optimisation.

  • Tumour PK and target occupancy
  • Biomarker-directed dose selection
  • PD endpoint validation
  • Combination index modelling

CNS & Neuroscience

CNS penetration studies, receptor occupancy by PET surrogate and behavioural PD end-points for neurological and psychiatric drug candidates.

  • Brain-to-plasma ratio determination
  • P-gp substrate assessment
  • Ex vivo receptor binding
  • Microdialysis sampling

Inflammation & Immunology

Mechanistic pharmacology for immunomodulatory compounds — cytokine inhibition profiling, immune cell functional assays and ex vivo whole blood pharmacodynamics.

  • Cytokine suppression EC50
  • Immune cell proliferation assays
  • Whole blood LPS stimulation
  • Multiplex cytokine profiling

Pharmacological Read-Outs We Deliver as Standard

All read-outs are pre-specified in the protocol and reported with complete statistical analysis in regulatory-ready format.

Pharmacokinetics

Cmax, AUC, t½, CL, Vd and bioavailability from multi-timepoint sampling. Tissue distribution and CSF penetration on request.

Pharmacodynamics

Target engagement, downstream biomarker modulation and functional read-outs linked directly to the PK profile via PK/PD modelling.

Safety Signals

Clinical observations, body weight, haematology, clinical chemistry and selected organ weights. hERG and in vivo cardiovascular endpoints as needed.

Statistical Analysis

ANOVA, Dunnett’s test, Kaplan-Meier and non-linear regression. All analyses conducted in GraphPad Prism with full methodology documented in the study report.

From Compound Brief to Final Report

A structured three-phase process designed to eliminate ambiguity and keep your programme on schedule.

Study Design & Feasibility

We review your compound profile, therapeutic indication and regulatory context. Our pharmacologists propose the most informative study design with full scientific justification and agreed success criteria.

GLP-Compliant Execution

Dosing, sampling, bioanalysis and pharmacodynamic assessments conducted under continuous quality oversight. Weekly status updates and real-time data access for your team throughout the study.

Analysis, Report & Debrief

PK/PD modelling, full statistical analysis and a regulatory-ready report delivered within agreed timelines, followed by a dedicated scientific debrief session with the study pharmacologist.

Our Pharmacology Track Record

200+ Pharmacology studies delivered across three therapeutic areas
ICH S7 Safety pharmacology studies aligned to A & B guidance
48h From compound brief to preliminary study design proposal
100% GLP-compliant reports accepted by EMA and FDA submissions

Ready to Characterise Your Compound?

Share your molecule profile and target indication. Our pharmacology team will outline a tailored study design within 48 hours.

Discuss your project